Enlivex Registers 10M Additional Shares for Resale, Quantifying Potential Dilution from $21M Note

summarizeSummary

Enlivex registered 10 million additional ordinary shares for resale by the holder of its $21 million convertible note, quantifying the maximum potential dilution from the financing. The shares would be issued upon conversion or repayment of the note, which carries a $40.38 conversion price—far above the current $1.94 stock price.

check_boxKey Events · Financing and Capital Events · ENLV

• 10M Additional Shares Registered for Resale

  An F-3 filing by Enlivex registers 10,000,000 additional ordinary shares for resale by Lind Global Asset Management XIV, LLC, the holder of its $21 million senior secured convertible note. This registration comes on top of 1,555,556 shares previously registered in April 2026.

• Potential Dilution from Note Conversion/Repayment

  The 10 million shares represent the company's good-faith estimate of the maximum number of shares issuable under the note. Although the note converts at $40.38 per share, the company can also repay principal in shares at a 10% discount to market, creating potential dilution at prices far below the conversion price.

• Overhang Relative to Outstanding Shares

  With 17.5 million shares outstanding, the 10 million additional shares registered represent a potential 57% increase in shares outstanding if fully issued and sold, though actual issuance depends on the company's repayment choices and the holder's conversion decisions.

• No Proceeds to Company

  Enlivex will not receive any proceeds from the resale of these shares; all proceeds go to the selling shareholder. The company already received $19 million in gross proceeds when the note was issued in March 2026.

auto_awesomeAnalysis · ENLV · Life Sciences

A new shelf registration from Enlivex permits the holder of its $21 million convertible note to resell up to 10 million additional ordinary shares, supplementing the 1.56 million shares already registered in April 2026. While the note—issued in March 2026—converts at $40.38 per share, far above the current $1.94 price, the company retains the option to repay principal in shares at a discount to market. This filing quantifies the maximum dilution risk: if all 10 million shares are issued and sold, they would create a significant overhang relative to the 17.5 million shares outstanding. The registration merely enables the holder to sell shares once issued; it does not confirm any sales have occurred. Coming on the heels of a recent reverse split and a $400 million private placement announced last week, this registration introduces another layer of potential dilution that investors need to monitor closely.